Download PDF
Neonatologie Scan 2014; 03(02): 139-150
DOI: 10.1055/s-0034-1365397
Fortbildung
© Georg Thieme Verlag KG Stuttgart · New York

Koffein zur Behandlung der Frühgeborenenapnoen

Axel Hübler
,
Christian Poets
Further Information

Publication History

Publication Date:
19 May 2014 (online)

Also available at
    Permissions and Reprints

Einleitung

In den letzten Jahren stellte die Etablierung der Therapie mit Methylxanthinen, insbesondere des Koffeins, in der Neonatologie eines der wichtigsten Elemente zur Behandlung der Frühgeborenenapnoen dar. Die Effektivität und Sicherheit der Behandlung wurde in einer Anzahl von Studien nachgewiesen. Koffein verbessert nicht nur die Apnoehäufigkeit selbst, sondern reduziert auch das Risiko für eine bronchopulmonale Dysplasie, eine Reintubation und einen offenen Ductus arteriosus Botalli [1]. Die Behandlung sehr kleiner Frühgeborener < 1250 g Geburtsgewicht ist in Zusammenhang mit der günstigeren Prognose der Patienten im Vergleich zur Placebogabe auch kosteneffektiver, zumindest anhand der Daten des kanadischen Gesundheitssystems [2].

 

  • Literatur

  • 1 Spitzer AR. Evidence-based methylxanthine use in the NICU. Clin Perinatol 2012; 39 (1) 137-148
    CrossrefGoogle Scholar
  • 2 Dukhovny D et al. Economic evaluation of caffeine for apnea of prematurity. Pediatrics 2011; 127 (1) e146-155
    CrossrefGoogle Scholar
  • 3 Supcun S et al. Caffeine increases cerebral cortical activity in preterm infants. J Pediatr 2010; 156 (3) 490-491
    CrossrefGoogle Scholar
  • 4 Rivkees SA, Wendler CC. Adverse and protective influences of adenosine on the newborn and embryo: implications for preterm white matter injury and embryo protection. Pediatr Res 2011; 69 (4) 271-278
    CrossrefGoogle Scholar
  • 5 Tanaka K et al. Comparative effects of respiratory stimulants on hypoxic neuronal cell injury in SH-SY5Y cells and in hippocampal slice cultures from rat pups. Pediatr Int 2013; 55 (3) 320-327
    CrossrefGoogle Scholar
  • 6 Kumral A et al. Genetic basis of apnoea of prematurity and caffeine treatment response: role of adenosine receptor polymorphisms: genetic basis of apnoea of prematurity. Acta Paediatr 2012; 101 (7) e299-e303
    CrossrefGoogle Scholar
  • 7 Clyman RI, Roman C. The effects of caffeine on the preterm sheep ductus arteriosus. Pediatr Res 2007; 62 (2) 167-169
    CrossrefGoogle Scholar
  • 8 Anderson BJ et al. Caffeine overdose in a premature infant: clinical course and pharmacokinetics. Anaesth Intensive Care 1999; 27 (3) 307-311
    Google Scholar
  • 9 Ergenekon E et al. Caffeine intoxication in a premature neonate. Paediatr Anaesth 2001; 11 (6) 737-739
    CrossrefGoogle Scholar
  • 10 Schmidt B et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006; 354 (20) 2112-2121
    CrossrefGoogle Scholar
  • 11 Schmidt B et al. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA 2012; 307 (3) 275-282
    CrossrefPubMedGoogle Scholar
  • 12 Schmidt B et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med 2007; 357 (19) 1893-1902
    CrossrefGoogle Scholar
  • 13 Francart SJ, Allen MK, Stegall-Zanation J. Apnea of prematurity: caffeine dose optimization. J Pediatr Pharmacol Ther 2013; 18 (01) 45-52
    Google Scholar
  • 14 Gray PH et al. Caffeine citrate for very preterm infants: Effects on development, temperament and behaviour. J Paediatr Child Health 2011; 47 (04) 167-172
    CrossrefGoogle Scholar
  • 15 Steer PA et al. Periextubation caffeine in preterm neonates: a randomized dose response trial. J Paediatr Child Health 2003; 39 (07) 511-515
    CrossrefGoogle Scholar
  • 16 Scanlon JE et al. Caffeine or theophylline for neonatal apnoea?. Arch Dis Child 1992; 67 (04) 425-428
    CrossrefGoogle Scholar
  • 17 Lee TC et al. Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. Clin Pharmacol Ther 1997; 61 (06) 628-640
    CrossrefGoogle Scholar
  • 18 Schoen K et al. Use of Methylxanthine Therapies for the Treatment and Prevention of Apnea of Prematurity. Paediatr Drugs 2014; 16: 169-177
    CrossrefGoogle Scholar
  • 19 Patel P et al. Dried blood spots and sparse sampling: a practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants. Br J Clin Pharmacol 2013; 75 (03) 805-813
    Google Scholar
  • 20 Natarajan G et al. Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise?. Pediatrics 2007; 119 (05) 936-940
    CrossrefGoogle Scholar
  • 21 Chavez ValdezR et al. Correlation between serum caffeine levels and changes in cytokine profile in a cohort of preterm infants. J Pediatr 2011; 158 (01) 57-64
    CrossrefGoogle Scholar
  • 22 Henderson-Smart DJ, De Paoli AG. Methylxanthine treatment for apnoea in preterm infants. Cochrane Database Syst Rev 2010; (12) CD000140
    Google Scholar
  • 23 Henderson-Smart DJ, Steer PA. Caffeine versus theophylline for apnea in preterm infants. Cochrane Database Syst Rev 2010; CD000273
    Google Scholar
  • 24 Martin RJ, Abu-Shaweesh JM. Control of breathing and neonatal apnea. Biol Neonate 2005; 87 (04) 288-295
    CrossrefGoogle Scholar
  • 25 Gannon BA. Theophylline or caffeine: which is best for apnea of prematurity?. Neonatal Netw 2000; 19 (08) 33-36
    Google Scholar
  • 26 Aiba T et al. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. J Am Coll Cardiol 2005; 45 (02) 300-307
    CrossrefGoogle Scholar
  • 27 Batchvarov VN et al. QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am J Physiol Heart Circ Physiol 2002; 282 (06) H2356-H2363
    CrossrefGoogle Scholar
  • 28 Drici MD, Barhanin J. Cardiac K+ channels and drug-acquired long QT syndrome. Therapie 2000; 55 (01) 185-193
    Google Scholar
  • 29 Miyata M et al. Dynamic QT/RR relationship of cardiac conduction in premature infants treated with low-dose doxapram hydrochloride. J Perinat Med 2007; 35 (04) 330-333
    Google Scholar
  • 30 Alvaro R et al. Small preterm infants (less than or equal to 1500 g) have only a sustained decrease in ventilation in response to hypoxia. Pediatr Res 1992; 32 (04) 403-406
    CrossrefGoogle Scholar
  • 31 Yost CS. A new look at the respiratory stimulant doxapram. CNS Drug Rev 2006; 12 (03) 236-249
    CrossrefGoogle Scholar
  • 32 Dani C et al. Brain hemodynamic effects of doxapram in preterm infants. Biol Neonate 2006; 89 (02) 69-74
    CrossrefGoogle Scholar
  • 33 Poets CF, Darraj S, Bohnhorst B. Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants. Biol Neonate 1999; 76 (04) 207-213
    CrossrefGoogle Scholar
  • 34 Sreenan C et al. Isolated mental developmental delay in very low birth weight infants: association with prolonged doxapram therapy for apnea. J Pediatr 2001; 139 (06) 832-837
    CrossrefGoogle Scholar
  • 35 Fischer C et al. Doxapram and hypokalaemia in very preterm infants. Arch Dis Child Fetal Neonatal Ed 2013; 98 (05) F416-F418
    CrossrefGoogle Scholar
  • 36 Greenwood DC et al. Caffeine intake during pregnancy, late miscarriage and stillbirth. Eur J Epidemiol 2010; 25 (04) 275-280
    CrossrefGoogle Scholar
  • 37 Jarosz M, Wierzejska R, Siuba M. Maternal caffeine intake and its effect on pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol 2012; 160 (02) 156-160
    CrossrefGoogle Scholar
  • 38 Laughon SK et al. Caffeine and insulin resistance in pregnancy. Am J Perinatol 2011; 28 (07) 571-578
    Article in Thieme ConnectGoogle Scholar
  • 39 Schmidt RJ et al. Caffeine, selected metabolic gene variants, and risk for neural tube defects. Birth Defects Res A Clin Mol Teratol 2010; 88 (07) 560-569
    CrossrefGoogle Scholar
  • 40 Browne ML et al. Maternal caffeine intake and risk of selected birth defects in the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 2011; 91 (02) 93-101
    CrossrefGoogle Scholar
  • 41 Hentges CR et al. Serum levels of caffeine in umbilical cord and apnea of prematurity. J Pediatr (Rio J) 2010; 86 (02) 137-142
    Google Scholar
  • 42 Loomans EM et al. Caffeine intake during pregnancy and risk of problem behavior in 5- to 6-year-old children. Pediatrics 2012; 130 (02) e305-e313
    CrossrefGoogle Scholar
  • 43 Santos IS, Matijasevich A, Domingues MR. Maternal caffeine consumption and infant nighttime waking: prospective cohort study. Pediatrics 2012; 129 (05) 860-868
    CrossrefGoogle Scholar
  • 44 Eichenwald EC, Aina A, Stark AR. Apnea frequently persists beyond term gestation in infants delivered at 24 to 28 weeks. Pediatrics 1997; 100 (03) 354-359
    CrossrefGoogle Scholar
  • 45 Comer AM, Perry CM, Figgitt DP. Caffeine citrate: a review of its use in apnoea of prematurity. Paediatr Drugs 2001; 3 (01) 61-79
    CrossrefPubMedGoogle Scholar
  • 46 Barrington K, Finer N. The natural history of the appearance of apnea of prematurity. Pediatr Res 1991; 29 (04) 372-375
    Google Scholar
  • 47 Henderson-Smart DJ. The effect of gestational age on the incidence and duration of recurrent apnoea in newborn babies. Aust Paediatr J 1981; 17 (04) 273-276
    Google Scholar
  • 48 Peter CS et al. Gastroesophageal reflux and apnea of prematurity: no temporal relationship. Pediatrics 2002; 109 (01) 8-11
    CrossrefGoogle Scholar
  • 49 Poets CF, Langner MU, Bohnhorst B. Effects of bottle feeding and two different methods of gavage feeding on oxygenation and breathing patterns in preterm infants. Acta Paediatr 1997; 86 (04) 419-423
    CrossrefGoogle Scholar
  • 50 Ruggins NR. Pathophysiology of apnoea in preterm infants. Arch Dis Child 1991; 66 (01) 70-73
    CrossrefGoogle Scholar
  • 51 Milner AD et al. Upper airways obstruction and apnoea in preterm babies. Arch Dis Child 1980; 55 (01) 22-25
    CrossrefGoogle Scholar
  • 52 Waggener TB et al. Mixed and obstructive apneas are related to ventilatory oscillations in premature infants. J Appl Physiol 1989; 66 (06) 2818-2826
    Google Scholar
  • 53 Martin RJ, Abu-Shaweesh JM, Baird TM. Apnoea of prematurity. Paediatr Respir Rev 2004; 5: 377-382
    CrossrefGoogle Scholar
  • 54 Gauda EB et al. Maturation of peripheral arterial chemoreceptors in relation to neonatal apnoea. Semin Neonatol 2004; 9 (03) 181-194
    CrossrefGoogle Scholar
  • 55 Poets CF. Atemregulation beim Neugeborenen. In: Jorch G, Hübler A. Neonatologie – Die Medizin des Früh- und Reifgeborenen. Stuttgart: Thieme; 2010: 181-184
    Article in Thieme ConnectGoogle Scholar
  • 56 Bandla HP et al. Protein kinase C modulates ventilatory patterning in the developing rat. Am J Respir Crit Care Med 1999; 159 (03) 968-973
    CrossrefGoogle Scholar
  • 57 Dreshaj IA et al. CO2-induced prolongation of expiratory time during early development. Respir Physiol 1999; 116 (02) 125-132
    CrossrefGoogle Scholar
  • 58 Dreshaj IA, Haxhiu MA, Martin RJ. Role of the medullary raphe nuclei in the respiratory response to CO2 . Respir Physiol 1998; 111 (01) 15-23
    CrossrefGoogle Scholar
  • 59 Duara S, Silva NetoG, Claure N. Role of respiratory muscles in upper airway narrowing induced by inspiratory loading in preterm infants. J Appl Physiol 1994; 77 (01) 30-36
    Google Scholar
  • 60 Wulbrand H, Von Zezschwitz G, Bentele KH. Submental and diaphragmatic muscle activity during and at resolution of mixed and obstructive apneas and cardiorespiratory arousal in preterm infants. Pediatr Res 1995; 38 (03) 298-305
    CrossrefGoogle Scholar
  • 61 Poets CF, Samuels MP, Southall DP. On sudden severe bradycardia secondary to hypoxemia. Pediatr Pulmonol 1992; 12 (01) 59-60
    Google Scholar
  • 62 Poets CF et al. Determinants of lung volume in spontaneously breathing preterm infants. Am J Respir Crit Care Med 1997; 155 (02) 649-653
    CrossrefGoogle Scholar
  • 63 Numa AH, Newth CJ. Anatomic dead space in infants and children. J Appl Physiol 1996; 80 (05) 1485-1489
    Google Scholar
  • 64 Fleming PJ, Bryan AC, Bryan MH. Functional immaturity of pulmonary irritant receptors and apnea in newborn preterm infants. Pediatrics 1978; 61 (04) 515-518
    Google Scholar
  • 65 Stransky A, Szereda-Przestaszewska M, Widdicombe JG. The effects of lung reflexes on laryngeal resistance and motoneurone discharge. J Physiol 1973; 231 (03) 417-438
    CrossrefGoogle Scholar
  • 66 Pickens DL, Schefft G, Thach BT. Prolonged apnea associated with upper airway protective reflexes in apnea of prematurity. Am Rev Respir Dis 1988; 137 (01) 113-118
    CrossrefGoogle Scholar
  • 67 Kattwinkel J. Neonatal apnea: pathogenesis and therapy. J Pediatr 1977; 90 (03) 342-347
    CrossrefGoogle Scholar
  • 68 Poets CF et al. Reduced haemoglobin levels in infants presenting with apparent life-threatening events – a retrospective investigation. Acta Paediatr 1992; 81 (04) 319-321
    CrossrefGoogle Scholar
  • 69 Rigatto H, Brady JP. Periodic breathing and apnea in preterm infants. II. Hypoxia as a primary event. . Pediatrics 1972; 50 (02) 219-228
    Google Scholar
  • 70 Poets CF, Pauls U, Bohnhorst B. Effect of blood transfusion on apnoea, bradycardia and hypoxaemia in preterm infants. Eur J Pediatr 1997; 156 (04) 311-316
    CrossrefGoogle Scholar
  • 71 Westkamp E et al. Blood transfusion in anemic infants with apnea of prematurity. Biol Neonat 2002; 82 (04) 228-232
    CrossrefGoogle Scholar
  • 72 Henderson-Smart DJ, Steer P. Methylxanthine treatment for apnea in preterm infants. Cochrane Database Syst Rev 2001; CD000140 3
    Google Scholar
  • 73 Perlman JM, Volpe JJ. Episodes of apnea and bradycardia in the preterm newborn: impact on cerebral circulation. Pediatrics 1985; 76 (03) 333-338
    Google Scholar
  • 74 Poets CF et al. The relationship between bradycardia, apnea, and hypoxemia in preterm infants. Pediatr Res 1993; 34 (02) 144-147
    CrossrefGoogle Scholar
  • 75 Poets CF, Roth B, Bohnhorst B. Therapie idiopathischer Apnoen, Bradykardien und Hypoxämien bei Frühgeborenen. AWMF 2009; Nr. 024/013 (GNPI)
    Google Scholar
  • 76 Vatlach S et al. Safety Profile Comparison between Extemporaneous and a Licensed Preparation of Caffeine Citrate in Preterm Infants with Apnea of Prematurity. Neonatology 2013; 105 (02) 108-111
    Google Scholar
  • 77 Henderson-Smart DJ, Davis PG. Prophylactic methylxanthines for endotracheal extubation in preterm infants. Cochrane Database Syst Rev 2010; CD000139 12
    Google Scholar
  • 78 Mathew OP. Apnea of prematurity: pathogenesis and management strategies. J Perinatol 2011; 31 (05) 302-310
    CrossrefGoogle Scholar